- Home
- DECK vs MDGL Comparison
DECK vs MDGL Comparison
Compare DECK & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DECK | MDGL |
|---|---|---|
| Founded | 1973 | 2011 |
| Country | United States | United States |
| Employees | N/A | 915 |
| Industry | Shoe Manufacturing | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.2B | 12.4B |
| IPO Year | 1996 | 2005 |
Fundamental Metrics
Financial Performance| Metric | DECK | MDGL |
|---|---|---|
| Price | $105.61 | $534.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 23 | 12 |
| Target Price | $122.45 | ★ $674.45 |
| AVG Volume (30 Days) | ★ 1.9M | 308.2K |
| Earning Date | 05-21-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 10.90 | ★ 41.32 |
| EPS | ★ 7.02 | N/A |
| Revenue | ★ $5,472,296,000.00 | $180,133,000.00 |
| Revenue This Year | $11.16 | $58.39 |
| Revenue Next Year | $6.96 | $48.55 |
| P/E Ratio | $14.82 | ★ N/A |
| Revenue Growth | ★ 9.76 | N/A |
| 52 Week Low | $78.91 | $286.75 |
| 52 Week High | $126.50 | $615.00 |
Technical Indicators
Market Signals| Indicator | DECK | MDGL |
|---|---|---|
| Relative Strength Index (RSI) | 50.42 | 54.32 |
| Support Level | $105.13 | $498.59 |
| Resistance Level | $115.40 | $545.29 |
| Average True Range (ATR) | 3.51 | 22.69 |
| MACD | -0.04 | 3.86 |
| Stochastic Oscillator | 70.37 | 46.15 |
Price Performance
Historical ComparisonAbout DECK Deckers Outdoor Corporation
Founded in 1973, California-based Deckers designs and sells casual and performance footwear, apparel, and accessories. In fiscal 2026, Ugg and Hoka accounted for 50% and 47% of total sales, respectively. The firm also markets a niche sandal brand Teva. Deckers produces most of its sales through wholesale partnerships but also operates e-commerce in more than 50 countries and has more than 200 company-operated stores, about half of which are outlets. The firm generated 58% of its fiscal 2026 sales in the United States.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.